DK1877070T3 - Terapeutisk anvendelse af TGF-beta2 antisense-oligonucleotider - Google Patents
Terapeutisk anvendelse af TGF-beta2 antisense-oligonucleotiderInfo
- Publication number
- DK1877070T3 DK1877070T3 DK06755024T DK06755024T DK1877070T3 DK 1877070 T3 DK1877070 T3 DK 1877070T3 DK 06755024 T DK06755024 T DK 06755024T DK 06755024 T DK06755024 T DK 06755024T DK 1877070 T3 DK1877070 T3 DK 1877070T3
- Authority
- DK
- Denmark
- Prior art keywords
- tgf
- antisense oligonucleotides
- therapeutic use
- oligonucleotide
- beta3
- Prior art date
Links
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 title 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 abstract 2
- 102000003814 Interleukin-10 Human genes 0.000 abstract 2
- 108090000174 Interleukin-10 Proteins 0.000 abstract 2
- 102100027584 Protein c-Fos Human genes 0.000 abstract 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 abstract 2
- 102100023132 Transcription factor Jun Human genes 0.000 abstract 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 abstract 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 abstract 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 abstract 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 2
- 229960002986 dinoprostone Drugs 0.000 abstract 2
- 229940076144 interleukin-10 Drugs 0.000 abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 2
- 101150082674 E2 gene Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05009802 | 2005-05-05 | ||
| US68049305P | 2005-05-13 | 2005-05-13 | |
| PCT/EP2006/062067 WO2006117400A2 (en) | 2005-05-05 | 2006-05-04 | Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1877070T3 true DK1877070T3 (da) | 2009-03-02 |
Family
ID=36370983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06755024T DK1877070T3 (da) | 2005-05-05 | 2006-05-04 | Terapeutisk anvendelse af TGF-beta2 antisense-oligonucleotider |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8097597B2 (es) |
| EP (2) | EP1877070B1 (es) |
| JP (2) | JP4977035B2 (es) |
| AT (1) | ATE418992T1 (es) |
| AU (2) | AU2006243218B2 (es) |
| BR (1) | BRPI0611452A2 (es) |
| CA (1) | CA2591586A1 (es) |
| CY (1) | CY1108944T1 (es) |
| DE (1) | DE602006004578D1 (es) |
| DK (1) | DK1877070T3 (es) |
| ES (1) | ES2319332T3 (es) |
| MX (1) | MX2007007184A (es) |
| NZ (1) | NZ562954A (es) |
| PL (1) | PL1877070T3 (es) |
| PT (1) | PT1877070E (es) |
| RU (1) | RU2427377C2 (es) |
| SI (1) | SI1877070T1 (es) |
| WO (1) | WO2006117400A2 (es) |
| ZA (2) | ZA200709237B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2591586A1 (en) | 2005-05-05 | 2006-11-09 | Antisense Pharma Gmbh | Dosage of oligonucleotides |
| EP1935428A1 (en) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
| US8822425B2 (en) | 2008-11-14 | 2014-09-02 | Antisense Pharma Gmbh | Dosage of oligonucleotides suitable for the treatment of tumors |
| KR101410560B1 (ko) * | 2008-11-14 | 2014-07-01 | 안티센스 파마 게엠베하 | 종양의 치료에 적합한 올리고뉴클레오티드의 용량 |
| KR101881596B1 (ko) | 2008-12-02 | 2018-07-24 | 웨이브 라이프 사이언시스 재팬 인코포레이티드 | 인 원자 변형된 핵산의 합성 방법 |
| SG10201403841QA (en) | 2009-07-06 | 2014-09-26 | Ontorii Inc | Novel nucleic acid prodrugs and methods of use thereof |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| EP2453017A1 (en) * | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
| JP6128529B2 (ja) | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | 官能化核酸の合成のための方法 |
| EP4219516A3 (en) | 2012-07-13 | 2024-01-10 | Wave Life Sciences Ltd. | Chiral control |
| BR112015000723A2 (pt) | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | adjuvante de ácido nucléico quiral |
| US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
| AU2014317961B2 (en) * | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| JP3019994B2 (ja) | 1987-11-30 | 2000-03-15 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法 |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| TW244371B (es) | 1992-07-23 | 1995-04-01 | Tri Clover Inc | |
| US5652355A (en) | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
| EP0695354B1 (en) | 1993-04-30 | 2002-01-09 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta1 (tgf-beta1) |
| DE69429617T2 (de) * | 1993-04-30 | 2002-08-22 | Biognostik Ges | Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1) |
| DE59407895D1 (de) | 1993-05-12 | 1999-04-15 | Novartis Ag | Nukleoside und Oligonukleotide mit 2'-Ethergruppen |
| DE69433520T2 (de) * | 1993-07-10 | 2004-11-11 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Antisense-nukleinsäure enthaltende pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zelltod, und zur behandlung von neoplasmen |
| US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
| DE69523680T2 (de) | 1994-08-02 | 2002-08-14 | Olympus Optical Co | Endoskopische Fassvorrichtung |
| US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| EP0856579A1 (en) | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
| DE69919869T2 (de) | 1998-06-10 | 2005-09-29 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | Stimulierung des immunsystems |
| EP1133988A1 (en) | 2000-03-11 | 2001-09-19 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| US7963956B2 (en) * | 2003-04-22 | 2011-06-21 | Antisense Pharma Gmbh | Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique |
| EP1694840A2 (en) * | 2003-12-19 | 2006-08-30 | Antisense Pharma GmbH | Combination therapy associating a tgf-beta antagonist with a chemotherapeutic agent |
| JP5650367B2 (ja) * | 2004-02-27 | 2015-01-07 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
| CA2591586A1 (en) | 2005-05-05 | 2006-11-09 | Antisense Pharma Gmbh | Dosage of oligonucleotides |
-
2006
- 2006-05-04 CA CA002591586A patent/CA2591586A1/en not_active Abandoned
- 2006-05-04 ES ES06755024T patent/ES2319332T3/es active Active
- 2006-05-04 PT PT06755024T patent/PT1877070E/pt unknown
- 2006-05-04 ZA ZA200709237A patent/ZA200709237B/xx unknown
- 2006-05-04 AT AT06755024T patent/ATE418992T1/de active
- 2006-05-04 SI SI200630221T patent/SI1877070T1/sl unknown
- 2006-05-04 NZ NZ562954A patent/NZ562954A/en not_active IP Right Cessation
- 2006-05-04 AU AU2006243218A patent/AU2006243218B2/en not_active Ceased
- 2006-05-04 EP EP06755024A patent/EP1877070B1/en active Active
- 2006-05-04 PL PL06755024T patent/PL1877070T3/pl unknown
- 2006-05-04 EP EP08173070.7A patent/EP2062586B1/en active Active
- 2006-05-04 RU RU2007145046/15A patent/RU2427377C2/ru not_active IP Right Cessation
- 2006-05-04 DE DE602006004578T patent/DE602006004578D1/de active Active
- 2006-05-04 WO PCT/EP2006/062067 patent/WO2006117400A2/en active Application Filing
- 2006-05-04 JP JP2007551691A patent/JP4977035B2/ja not_active Expired - Fee Related
- 2006-05-04 US US11/792,041 patent/US8097597B2/en not_active Expired - Fee Related
- 2006-05-04 MX MX2007007184A patent/MX2007007184A/es active IP Right Grant
- 2006-05-04 DK DK06755024T patent/DK1877070T3/da active
- 2006-05-04 BR BRPI0611452-0A patent/BRPI0611452A2/pt not_active Application Discontinuation
-
2008
- 2008-10-31 ZA ZA2008/09354A patent/ZA200809354B/en unknown
-
2009
- 2009-03-27 CY CY20091100366T patent/CY1108944T1/el unknown
- 2009-12-10 JP JP2009280553A patent/JP2010090159A/ja active Pending
- 2009-12-17 AU AU2009251023A patent/AU2009251023B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007007184A (es) | 2008-01-14 |
| WO2006117400A2 (en) | 2006-11-09 |
| NZ562954A (en) | 2009-10-30 |
| BRPI0611452A2 (pt) | 2010-09-08 |
| CA2591586A1 (en) | 2006-11-09 |
| PT1877070E (pt) | 2009-03-13 |
| AU2009251023B2 (en) | 2012-02-02 |
| RU2007145046A (ru) | 2009-06-10 |
| PL1877070T3 (pl) | 2009-06-30 |
| EP1877070B1 (en) | 2008-12-31 |
| RU2427377C2 (ru) | 2011-08-27 |
| US20090306176A1 (en) | 2009-12-10 |
| EP2062586A3 (en) | 2009-08-12 |
| EP2062586B1 (en) | 2017-03-15 |
| JP2008528460A (ja) | 2008-07-31 |
| JP2010090159A (ja) | 2010-04-22 |
| AU2009251023A1 (en) | 2010-01-14 |
| ES2319332T3 (es) | 2009-05-06 |
| CY1108944T1 (el) | 2014-07-02 |
| EP2062586A2 (en) | 2009-05-27 |
| US8097597B2 (en) | 2012-01-17 |
| EP1877070A2 (en) | 2008-01-16 |
| ZA200809354B (en) | 2010-02-24 |
| ATE418992T1 (de) | 2009-01-15 |
| AU2006243218B2 (en) | 2009-09-17 |
| WO2006117400A3 (en) | 2007-01-25 |
| JP4977035B2 (ja) | 2012-07-18 |
| ZA200709237B (en) | 2009-04-29 |
| DE602006004578D1 (de) | 2009-02-12 |
| AU2006243218A1 (en) | 2006-11-09 |
| SI1877070T1 (sl) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1877070T3 (da) | Terapeutisk anvendelse af TGF-beta2 antisense-oligonucleotider | |
| EA200870528A1 (ru) | Композиции и способы ингибирования экспрессии гена pcsk9 | |
| AR039717A1 (es) | Construcciones de arn de intrones cadena doble y usos de las mismas | |
| NO20084738L (no) | Forbindelser og fremgangsmater for modulering av ekspresjonen av PCSK9 | |
| WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
| WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
| SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
| ATE460481T1 (de) | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung | |
| JP2015142558A5 (es) | ||
| JP2014511686A5 (es) | ||
| WO2007051045A3 (en) | Compositions and methods for inhibiting expression of huntingtin gene | |
| WO2007128477A3 (en) | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION | |
| ATE476441T1 (de) | Wirksame lna-oligonukleotide zur inhibierung von hif-1a | |
| NZ593618A (en) | Gnaq targeted dsrna compositions and methods for inhibiting expression | |
| ATE528008T1 (de) | Rnai-modulation von aha und ihre therapeutische verwendung | |
| WO2008036638A3 (en) | Rnai modulation of scap and therapeutic uses thereof | |
| ATE522607T1 (de) | Sense-oligonukleotid mit fähigkeit zur kontrolle der expression von inos sowie dieses umfassende zusammensetzung | |
| WO2007127919A3 (en) | Compositions and methods for inhibiting expression of a gene from the jc virus | |
| MX2009002462A (es) | Siarn y metodos de manufactura del mismo. | |
| RU2013102545A (ru) | Связывающая vegfa си-рнк и способы лечения in vivo | |
| WO2007137220A3 (en) | Compositions and methods for inhibiting expression of ikk-b gene | |
| ATE510545T1 (de) | Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen | |
| JP2007517498A5 (es) | ||
| WO2008041933A3 (en) | Rna interference against wrap53 to treat hyperproliferative diseases | |
| WO2007087544A3 (en) | Novel compositions of chemically modified small interfering rna |